



3rd International Conference on

PharmScience Research & Development

Pharma R&D-2021

February 22-24, 2021 | Virtual

Last updated: January 19, 2021

Presentation Slots are Available. Book your Slot at:

https://pharma-rd.com/registration_form

Day 1 | February 22, 2021

Keynote Presentations

Meeting Timezone (PST) 07:00-07:30	Local Time 17:00-17:30	The Cannabinoids: Looking Back and Ahead Raphael Mechoulam , Hebrew University of Jerusalem, Israel H-Index: 122, Wikipedia: https://en.wikipedia.org/wiki/Raphael_Mechoulam
---	------------------------------	---





Prof. Mechoulam is with the Department of Medicinal Chemistry and Natural Products at the Faculty of Medicine. He is former Rector of the University and is a member of the Israel Academy of Sciences. His research interests are in the field of the chemistry and biological activity of natural products and medicinal agents. His main contributions are in the field of the constituents of cannabis and the endogenous cannabinoids found in the brain and the periphery. He has published extensively on their pharmacological activities.


Meeting Timezone (PST) 07:30-08:00	Local Time 15:30-16:00	Structural Biology, Bioinformatics and Drug Discovery: Learning from Cancer to Target Mycobacterial Infections for Tuberculosis, Leprosy and Cystic Fibrosis Tom Blundell , University of Cambridge, UK H-Index: 119, Wikipedia: https://en.wikipedia.org/wiki/Tom_Blundell
---	------------------------------	---





Sir Thomas Leon Blundell, FRS FRSC FMedSci MAE is a British biochemist, structural biologist, and science administrator. He was a member of the team of Dorothy Hodgkin that solved in 1969 the first structure of a protein hormone, insulin. (citation needed) Blundell has made contributions to the structural biology of polypeptide hormones, growth factors, receptor activation, signal transduction, and DNA double-strand break repair, subjects important in cancer, tuberculosis, and familial diseases. (11) He has developed software for protein modelling and understanding the effects of mutations on protein function, leading to new approaches to structure-guided and Fragment-based lead discovery. In 1999 he co-founded the oncology company Astex Therapeutics, which has moved ten drugs into clinical trials. Blundell has played central roles in restructuring British research councils and, as President of the UK Science Council, in developing professionalism in the practice of science.

Meeting Timezone (PST) 08:00-08:30	Local Time 11:00-11:30	Purinergic Signaling: Impact of GPCR Structures on Rational Drug Kenneth A. Jacobson , National Institutes of Health, Bethesda, MD H-Index: 107
		<p>Dr. Jacobson has authored or co-authored over 500 scientific publications and is an inventor on 35 issued U.S. patents. He has served the ACS Division of Medicinal Chemistry as Chair in 2004 and has planned and chaired numerous symposia at ACS National Meetings. Dr. Jacobson is or has been on the editorial advisory boards of the Journal of Medicinal Chemistry, Bioconjugate Chemistry, Molecular Pharmacology, Current Topics in Medicinal Chemistry, Medicinal Research Reviews, and Future Medicinal Chemistry, and he is an Associate Editor of Purinergic Signalling. He has mentored 63 postdoctoral fellows, both chemists and biologists. He received the 2003 Hillebrand Prize, the 2008 Sato International Memorial Prize from the Pharmaceutical Soc. of Japan, and the 2009 Pharmacia-ASPET Award from the American Soc. for Pharmacology and Experimental Therapeutics. Dr. Jacobson was recently included in a listing of the ten most cited researchers in the field of pharmacology.</p>

Meeting Timezone (PST) 08:30-09:00	Local Time 08:30-09:00	Discovery of "New" GPCRs as Potential Therapeutic Targets Paul A Insel , University of California, San Diego, CA H-Index: 107
		<p>Dr. Insel received research training at the NIH and UCSF before joining the faculty at UCSF and subsequently UCSD, where he is currently Vice-Chair and Distinguished Professor of Pharmacology and Medicine. He is also the Director of the UCSD Medical Scientist (M.D./Ph.D.) Training Program. He holds a Doc. Hon Causa from the University of Paris, is a Fellow, American Association for the Advancement of Science and has received other awards and honors. Dr. Insel has served as Associate/Editor of numerous scientific journals and is currently Editor of the Annual Review of Pharmacology and Toxicology and co-Head of Faculty of the Faculty of 1000Prime in Pharmacology and Drug Discovery.</p>

Meeting Timezone (PST) 09:00-09:30	Local Time 09:00-09:30	Skin Bioengineering Insight into Your Kidney, Liver and Brain Howard Maibach , University of California, San Francisco, CA Wikipedia: https://en.wikipedia.org/wiki/Howard_Maibach
		<p>Dr. Howard Maibach is a dermatologist with expertise in treating contact dermatitis (a rash caused by touching an irritating substance) and occupational dermatitis (a rash resulting from workplace exposure to an irritating substance). His specialties include allergic skin disorders and skin conditions caused by exposure to toxic substances. He also has an interest in dermatopharmacology, the study of medications for skin disorders. He is a member of 19 professional societies, including the American Academy of Dermatology, San Francisco Dermatological Society and International Commission on Occupational Health.</p>

Meeting Timezone (PST) 09:30-10:00	Local Time 09:30-10:00	Discovering Drugs or Leads with Beneficial Multi-Target Pharmacology in Infectious Diseases and Cancer
		Ruben Abagyan , University of California, San Diego, CA H-Index: 89
		<p>Dr. Ruben Abagyan is a Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, which he joined in 2009. He received his Master's and Ph.D. degree in molecular physics at MPTI and MSU. At the European Molecular Biology Laboratory in Heidelberg he developed internal coordinate mechanics and structural docking approach (ICM) for modeling and docking. He received his tenure at New York University and Courant Institute of Mathematics, and continued at Novartis Functional Genomics Institute and the Scripps Research Institute. Dr. Abagyan serves on international review panels for Institutes in Switzerland, UK, EU and Hong Kong. He received CapCure awards, Princess Diana Award and medal in Sydney, Australia, American Association of Colleges of Pharmacy Teacher of the Year award and UCSD-SSPPS 'Faculty of the Year' awards. R.A. authored and co-authored 300 research papers and book chapters.</p>

Meeting Timezone (PST) 10:00-10:30	Local Time 12:00-12:30	Treatment of Neuropatic Pain with Agents that do not Develop Tolerance and Addiction and are Non Opioids
		James M Cook , University of Wisconsin, Milwaukee, WI H-Index: 69
		<p>Dr. James M Cook received his Ph.D. degree in organic chemistry in 1971. He then was awarded an NIH Postdoctoral Fellowship and went to the University of British Columbia where he continued his studies in the field of alkaloid chemistry with Professor James P. Kutney from 1972-1973. In the fall of 1973, Jim was appointed Assistant Professor of Chemistry at the University of Wisconsin-Milwaukee. He was later promoted to Associate Professor in 1979 and Professor of Chemistry in 1986. He served as Chairman of the Department of Chemistry at UWM from 1996-1999. Finally in 2002, he was recognized for his scholarly achievement and academic contributions by promotion to the rank of University Distinguished Professor of Chemistry.</p>

Keynote Slots are Available

10:30-10:40

Coffe Break

Session I: Drug

Drug Discovery | Drug Design | Drug Development | Drug Delivery | Drug Metabolism

Meeting Timezone (PST)	Local Time	Chairs: To be Announced
10:40-11:00	19:40-20:00	Development of ArnT-Mediated Colistin Resistance Diterpene-Based Inhibitors Francesca Ghirga , Istituto Italiano di Tecnologia, Italy
11:00-11:20	22:00-22:20	New Sensitive Derivatization Methodology of Levofloxacin Antibiotic from its Dosage Formulations: Kinetic Spectrophotometric Methods for Determination Roula Bayram , Batterjee Medical College, Saudi Arabia
11:20-11:40	14:20-14:40	Empirical Profile Bayesian Estimation for Extrapolation of Historical Adult Data to Pediatric Drug Development Yaoshi Wu , Senior Principle Statistician, Boehringer Ingelheim, CT
11:40-12:00	14:40-15:00	Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases Bin Ma , Senior Scientist, Biogen, MA
12:00-12:20	14:00-14:20	Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management Wolfgang Sadee , Chief Scientific Officer, Aether Therapeutics, TX
12:20-12:40	15:20-15:40	A Divergent Total Synthesis of Streptothricin F Roman Manetsch , Northeastern University, MA
12:40-13:10		Lunch Break
13:10-13:30	15:10-15:30	Dense Nanolipid Fluid (DNLF) Dispersions for Topical Drug Delivery: Single Step Synthesis Using a Modified Twin Screw Extruder, Drug Properties and Skin Permeation Eric D. Morrison , Senior Scientist, Dynation LLC, MN
13:30-13:50	16:30-16:50	Synthesis of Novel Heteroaromatic Compounds Using Pyrroles Generated from Dihydropyridones Sezgin Kiren , Winston-Salem State University, NC
13:50-14:10	16:50-17:10	N-Alkyl Phenylimidazolidones as a New Class of Antimicrotubule Prodrugs Targeting Breast Cancers Sebastien Fortin , Laval University, Canada
14:10-14:30	17:10-17:30	The Potential of (19)F NMR Application in GPCR Biased Drug Discovery Libin Ye , University of South Florida, FL
14:30-14:50	16:30-16:50	In Silico Design and Experimental Validation of Combination Therapy for Pancreatic Cancer Aniruddha Datta , Texas A & M University, TX

14:50-15:10	06:50-07:10 Feb 23, 2021	Emergence of Allosteric Drug-Resistance Mutations: New Challenges for Allosteric Drug Discovery Tyler Yu , Nutshell Biotech Co. Ltd., China
15:10-15:30	07:10-07:30 Feb 23, 2021	How does the Nature of an Excipient and the Condition of an Atheroma Influence Drug-Coated Balloon Therapy? Karthic Anbalakan , National University of Singapore, Singapore
15:30-15:40 Coffee Break		
15:40-16:00	18:40-19:00	Title to be Announced Mei X. Wu , Harvard University, MA
16:00-16:20	16:00-16:20	Silicone Oil Particles in Prefilled Syringes With Human Monoclonal Nate H. Joh , Senior Scientist/Manager, Amgen, CA
16:20-16:40	16:20-16:40	Title to be Announced Venkata Yenugonda , John Wayne Cancer Institute, CA
16:40-17:00	16:40-17:00	Title to be Announced Joshua Tokuda , Postdoctoral Fellow, Amgen, CA

Poster Presentations		
Meeting Timezone (PST)	Local Time	Poster Presentations will be updated in the website and the link will be shared to all the participants. Time Allotted for queries: 5 minutes
17:00-17:05	19:00-19:05	Synthesis of (15,15,15-2H3)-Dihydroartemisinic Acid and Mechanistic Studies of Endoperoxide Formation to Artemisinin from Dihydroartemisinic Acid Kaitlyn Varela , The University of Texas at San Antonio, TX
17:05-17:10	19:05-19:10	Regulation of Cataract Formation in Bovine Lenses by Diallyl Trisulfide Catherine A Opere , Creighton University, NE
17:10-17:15	10:10-10:15 Feb 23, 2021	Improved Hepatic Delivery of siRNA by Condensed Drug Loading in a Dimpled Suppository Akihiro Matsumoto , Osaka Ohtani University, Japan
17:15-17:20	03:15-03:20 Feb 23, 2021	Potential Use of Extracts from the Plants <i>Angelica sinensis</i> , <i>Cymbopogon citrates</i> , <i>Rosa canina</i> and <i>Salvia officinalis</i> , in Skin and Hair Care Products Michael Plioukas , University of Nicosia, Cyprus
17:20-17:25	03:20-03:25 Feb 23, 2021	Comparison between Traditional Phytotherapy and Scientifically-Proven Documented Phytotherapy: <i>Salvia officinalis</i> Michael Plioukas , University of Nicosia, Cyprus
17:25-17:30	03:25-03:30 Feb 23, 2021	Potential Use of Extracts from the Plants <i>Arctium lappa</i> , <i>Chondrus crispus</i> , <i>Mentha arvensis</i> , <i>Ricinus communis</i> , <i>Rumex crispus</i> , <i>Swertia japonica</i> , <i>Taraxacum officinale</i> , <i>Thymus serpyllum</i> and <i>Tussilago farfara</i> , in Skin and Hair Care Products Michael Plioukas , University of Nicosia, Cyprus

Day 2 | February 23, 2021

Model-informed ADME in Drug Discovery and Development		
Meeting		
Timezone	Local Time	Chair: Prashant Desai, Director-ADME, Eli Lilly and Company, IN
(PST)		
07:00-07:10	10:00-10:10	Opening Remarks and Introduction Prashant V Desai , Director-ADME, Eli Lilly and Company, IN
07:10-07:40	10:10-10:40	Use of Mechanistic Pharmacokinetics for Human PK Projection in Late Drug Discovery Dandan Tian , Research Scientist, Eli Lilly and Company, IN
07:40-08:10	10:40-11:10	Integration of Computational ADME Modeling to Drive Drug Discovery Zhaomin Liu , Research Scientist, Eli Lilly and Company, IN
08:10-08:40	11:10-11:40	Biopharmaceutics Modeling to Understand Absorption and Support Formulation Selection Prior to First in Human Dose Stephen Stamatis , Senior Consultant Engineer, Eli Lilly and Company, IN
08:40-09:10	10:40-11:10	Global Analysis of Models to Predict Human Fraction Absorbed Edward Price , Senior Scientist, AbbVie, IL
09:10-09:40	09:10-09:40	Data Driven Computational ADME: From Artificial Intelligence to Human Knowledge Fabio Broccatelli , Senior Scientist, Genentech, CA
09:40-10:10	09:40-10:10	Incorporating Physico-Chemical Properties in the Design of New Drugs: Large Scale IVIVc and Physiological Modeling to Enable Trend Analysis in Early Drug Discovery Wenyi Wang , Associate Scientist, Genentech, CA
10:10-10:40	10:10-10:40	High-Throughput Dose Projection with In-House PBPK Models in Early Phase Drug Discovery Yanran Wang , Associate Scientist, Genentech, CA
10:40-10:50 Coffee Break		

Session II: Pharmacology

Meeting Timezone (PST)	Local Time	Chairs: To be Announced
10:50-11:10	19:50-20:10	Serotonergic Metamodulation of mGlu2/3 Autoreceptors in the Spinal-Cord as a Novel Approach for the Cure of Neuropathic Pain <i>Guendalina Olivero</i> , University of Genoa, Italy
11:10-11:30	20:10-20:30	Cannabidiol-Induced Autophagic Pathway in Chronic Myeloid Leukemia Cells <i>Federica Maggi</i> , University of Rome, Italy
11:30-11:50	20:30-20:50	Impact of Organic Sunscreens on Human Health and Natural <i>Anna W. Sobańska</i> , Medical University of Lodz, Poland
11:50-12:10	20:50-21:10	Cannabinoids Activity in Endometrial Cancer <i>Oliviero Marinelli</i> , University of Camerino, Italy
12:10-12:30	21:10-21:30	Emerging Role of TRPML1 in Cancer <i>Maria Beatrice Morelli</i> , University of Camerino, Italy
12:30-12:50	21:30-21:50	Neurological Abnormalities in the FUS-tg Mice Mimic Amyotrophic Lateral Sclerosis: Effects of New Therapies and their Possible use for the Medicinal Food <i>Tatiana Strekalova</i> , Maastricht University, The Netherlands
12:50-13:20		Lunch Break
13:20-13:40	22:20-22:40	Sustainable Chemistry to Access P2X7R Modulators Targeting IBD and Associated Cancers <i>Alina Ghinet</i> , Scientist, Yncrea, France
13:40-14:00	22:40-23:00	A Rare Case of Osmium Tetroxide Intoxication: Management of <i>Natalie Friedova</i> , Charles University, Czech Republic
14:00-14:20	23:00-23:20	Title to be Announced <i>Concettina La Motta</i> , University of Pisa, Italy
14:20-14:40	22:20-22:40	First in Class, First in Humans, Small Activating RNA to CEBP Alpha in Myeloid Cells <i>Nagy A Habib</i> , Imperial College London, UK
14:40-15:00	22:40-23:00	Evaluating a Role for Cathepsin S in Acute and Chronic Lung Disease <i>Clifford C Taggart</i> , Queen's University Belfast, UK
15:00-15:20	18:00-18:20	Put Your Toxicology Where Your Mouth Is <i>Amy Reisinger</i> , CEO, SteelFusion Clinical Toxicology Laboratory, LLC, PA
15:20-15:40	18:20-18:40	Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding <i>Juan Marugan</i> , National Institutes of Health, MD
15:40-15:50		Coffee Break

15:50-16:10	17:50-18:10	Title to be Announced Luz Irene Pascual Mathey , Universidad Veracruzana, Mexico
16:10-16:30	19:10-19:30	microRNA Crosstalk Influences Epithelial- to- Mesenchymal, Endothelial- to- Mesenchymal, and Macrophage- to- Mesenchymal Transitions in the Kidney Swayam Prakash Srivastava , Yale University, CT
16:30-16:50	19:30-19:50	Title to be Announced Mohamed Hafez Mahmoud , Scientist, Honessan Pharma, Canada
16:50-17:10	16:50-17:10	Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc 3-Conjugated Antisense Oligonucleotides Yanfeng Wang , Executive Director, Ionis Pharmaceuticals, Inc., CA
17:10-17:30	17:10-17:30	Title to be Announced Minsun Song , Beckman Research Institute of City of Hope, CA
17:30-17:50	09:30-09:50 Feb 24, 2021	The Therapeutic Effect of Artemisinin on Alzheimers Disease Wenhua Zheng , University of Macau, Macau SAR
17:50-18:10	04:50-05:10 Feb 24, 2021	Relationship between Dynamic Conformation and the Activity and Functionality of MERS-CoV or Zika Viruses Ahmed Alaofi , King Saud University, Saudi Arabia

Day 3 | February 24, 2021

Session III: Pharma Industry		
Case Studies Analysis GMP, GDP, and GCP Clinical Trials Education Formulations		
Meeting Timezone (PST)	Local Time	Chairs: To be Announced
07:00-07:20	10:00-10:20	Real-World Data Curation to Transform Medical Investigation: Technology to Reimagine the Economics of Evidence Gathering and Aaron Leibtag , CEO & Cofounder, Pentavere, Canada
07:20-07:40	10:20-10:40	Putative Phospholipase B-Like 2 is not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products Sisi Zhang , Senior R&D Specialist, Regeneron Pharmaceutical, NY
07:40-08:00	09:40-10:00	Hydrophobic Interaction Chromatography (HIC) Method Development and Characterization of Resolved Drug-Load Variants in Site-Specifically Conjugated Pyrrolbenzodiazepine Dimer-Based Antibody Drug Conjugates (PBD-ADCs) Thamara Janaratne , Principal Research Scientist I, AbbVie, IL

08:00-08:20	10:00-10:20	SANE Nanosensing: A New Technology for Ultrasensitive Screening of Antibody-Ligand Interactions with Up To 1000-Fold Savings in Protein Reagents George Alexandrakis , University of Texas at Arlington, TX
08:20-08:40	11:20-11:40	Early Clinical Trials of Toca 511 and Toca FC Show a Promising Novel Treatment for Recurrent Malignant Glioma David Cory Adamson , Emory Healthcare, GA
08:40-09:00	11:40-12:00	Quantitative Differentiation of Protein Aggregates from Other Subvisible Particles in Viscous Mixtures Through Holographic Characterization Laura A Phillips , CEO & Founder, Spheryx, Inc, NY
09:00-09:20	17:00-17:20	Right First and Every Time Suzanne Pavon , Executive Vice President, TFS International, UK
09:20-09:40	18:20-18:40	Evaluation of an Adaptive Seamless Design for a Phase II/III Clinical Trial in Recurrent Events Data to Demonstrate Reduction in Number of Acute Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) Daniela Casula , Project Statistician, GSK, Italy
09:40-10:00	19:40-20:00	Exploring Case-Based Learning and Graduate Attributes in Pharmacy Education at a South African University Vanessa Singh , University of KwaZulu-Natal, South Africa
10:00-10:20	21:30-21:50	Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial Sina Salari , Shahid Beheshti University of Medical Sciences, Iran
10:20-10:30 Coffee Break		
10:30-10:50	13:30-13:50	Research Obstacles and Problem Solving in Scientific R&D Teams David J. McBee , UNC Kenan-Flagler Business School, NC
10:50-11:10	13:50-14:10	Healing the U. S. Healthcare Delivery System Elizabeth A. Regan , University of South Carolina, SC
11:10-11:30	11:10-11:30	Title to be Announced Tze Leung Lai , Stanford University, CA
11:30-11:50	11:30-11:50	Documentation Trifecta Liimu Mcgill , CEO, LSM Consulting, CA
11:50-12:10	19:50-20:10	Pluronic-Based Nanovehicles: Recent Advances in Anticancer Therapeutic Applications Ivana Jarak , University of Coimbra, Portugal
12:10-12:30	22:10-22:30	The Israeli Phage Bank (IPB) Ortal Yerushalmy , Hebrew University of Jerusalem, Israel
12:30-12:50	14:30-14:50	Regenerative Medicine: Successful Translation of Basic Science Research from the Bench to the Clinic Madhu S Dhar , University of Tennessee, TN
12:50-13:20 Lunch Break		
13:20-13:40	16:20-16:40	SCIMON Gastric Cancer Dashboard: A Novel Tool for Real-World Evidence and Insights Leveraging Data Visualization Arturo Loaiza-Bonilla , Senior Medical Director, Vidence, FL

13:40-14:00	16:40-17:00	Take your CBD with Food! Gus R. Rosania , University of Michiga, MI
14:00-14:20	14:00-14:20	Devising a Tier- based Skin Sensitisation Screening Strategy for Personal Care and Cosmetic Products Andrew Monnot , Principal Health Scientist, Cardno ChemRisk, CA
14:20-14:40	15:20-15:40	Measurement, modeling and QALYs Paul Langley , Director, Maimon Research LLC, AZ
14:40-15:00	07:40-08:00 Feb 25, 2021	Immunogenicity Case Studies and De-Immunitization Strategy in Chiyomi Kubo , Principal Scientist, Chugai Pharmaceutial Co.,Ltd., Japan
15:00-15:20	07:00-07:20 Feb 25, 2021	Title to be Announced Steven LOH Cheng Toa , Nanyang Technological University, Singapore
15:20-15:40	07:20-07:40 Feb 25, 2021	A New Era for the Development of Nebulizers Edgar Hernan Cuevas Brun , Marketing Manager, HCmed Innovations, Taiwan
15:40-16:00	07:40-08:00 Feb 25, 2021	Pharmacogenomics and Personalized Medicine Study of Wenhua Zheng , University of Macau, Macau SAR
16:00-16:20	05:30-05:50 Feb 25, 2021	Title to be Announced Jinitha Anu Saji , Caritas College of Pharmacy, India

16:00-16:10

Coffee Break

Session IV: COVID 19		
Meeting Timezone (PST)	Local Time	Chairs: To be Announced
16:10-16:30	17:10-17:30	Prediction of Coronavirus Infections and Complications at the Individual and the Population Levels from Genomic, Proteomic, Clinical and Behavioral Data Sources Judith Klein , Colorado School of Mines, CO
16:30-16:50	16:30-16:50	Therapeutic Potentials of DNA Aptamer-Based Designer DNA Nanostructures in COVID-19 Weishan Huang , Louisiana State University, LA
16:50-17:10	19:50-20:10	Prototype of a Medical Mask Using a Novel Antimicrobial / Antiviral Biofilter Material Gloria S Oporto-Velasquez , West Virginia University, WA
17:10-17:30	20:10-20:30	A Privacy-Preserving Contact Tracing System for COVID-19 Containment and Mitigation Yaling Yang , Virginia Tech, VA
17:30-17:50	20:30-20:50	Simulating Preventative Testing of SARS-CoV-2 in Schools: Policy Jianhong Wu , York University, Canada
17:50-18:10	07:20-07:40 Feb 25, 2021	Interactions of Peptide Coated Gold Nanoparticles with Spike Protein of the SARS-CoV-2: A Basis for Design of a Simple and Rapid Detection Tool Beena Rai , Principal Scientist, TCS, India
18:10-18:30	04:10-04:30 Feb 25, 2021	The University of South Africa (UNISA) Responding to the New World Order Post Covid-19 Mandla Makhanya , UNISA, South Africa

Last minute changes due to functional, private, or organizational needs can be necessary.

Program is subject to change